Investigating the effect of magnesium oxide supplementation on the quality of life of patients with cardiorenal syndrome caused by chronic heart failure with reduced ejection - A single-arm clinical trials

Inclusion criteria:

Age over 18 years Outpatients referred to the clinic diagnosed with chronic heart failure (ECO result with EF less than 40%) Patients with renal failure or evidence of renal damage (decrease in GFR below normal for more than 3 months or albuminuria above 30 mg/dl in 24-hour urine) GFR more than 30 mL/min Serum magnesium below 2 mg/dl

Exclusion criteria:

Current treatment with hemodialysis or peritoneal dialysis Donated kidney recipient or kidney donor Coronary artery bypass grafting Previous parathyroidectomy Hyperparathyroidism Current treatment with medication or supplements containing magnesium (antacids) Recent history of treatment with medicine or supplements containing magnesium Any condition that interferes with the absorption of magnesium from the digestive system (short bowel syndrome / chronic pancreatitis) Pregnant mothers, mothers during breastfeeding Allergy to the contents of the medicine Patient participation in other intervention trials Hypothyroidism and hyperthyroidism Patients showing features of other primary kidney diseases Urinary tract infection Any fever associated with infection Active malignancies Liver cirrhosis and chronic alcoholism All people who used cigarettes and other tobacco products ESRD and stage five CKD Laxatives and other nephrotoxic drugs

Target sample size: 30